Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)
Latest Information Update: 21 Jan 2022
Price :
$35 *
At a glance
- Drugs Vortioxetine (Primary) ; Fluoxetine
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Lundbeck A/S
- 11 Jan 2022 Primary endpoint has not been met(Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment) as per Results published in the Journal of the American Academy of Child and Adolescent Psychiatry
- 11 Jan 2022 Results published in the Journal of the American Academy of Child and Adolescent Psychiatry
- 08 Aug 2019 Status changed from active, no longer recruiting to completed.